Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM. Karthaus M, et al. Support Care Cancer. 2015 Oct;23(10):2917-23. doi: 10.1007/s00520-015-2657-1. Epub 2015 Feb 28. Support Care Cancer. 2015. PMID: 25724407 Free PMC article. Clinical Trial.
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H. Aapro M, et al. Among authors: karthaus m. Support Care Cancer. 2017 Apr;25(4):1127-1135. doi: 10.1007/s00520-016-3502-x. Epub 2016 Nov 24. Support Care Cancer. 2017. PMID: 27885469 Free PMC article. Clinical Trial.
Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM. Herrstedt J, et al. Among authors: karthaus m. Support Care Cancer. 2019 Jul;27(7):2699-2705. doi: 10.1007/s00520-018-4564-8. Epub 2018 Nov 28. Support Care Cancer. 2019. PMID: 30488222 Clinical Trial.
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V. Schwartzberg L, et al. Among authors: karthaus m. Cancer Med. 2019 May;8(5):2064-2073. doi: 10.1002/cam4.2091. Epub 2019 Apr 9. Cancer Med. 2019. PMID: 30968588 Free PMC article. Clinical Trial.
Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy.
Schilling J, Kurbacher CM, Hanusch C, Busch S, Holländer M, Kreiss-Sender J, Rezek D, Flahaut E, Karthaus M. Schilling J, et al. Among authors: karthaus m. Breast Care (Basel). 2022 Apr;17(2):130-136. doi: 10.1159/000514891. Epub 2021 May 25. Breast Care (Basel). 2022. PMID: 35702496 Free PMC article.
201 results